132 related articles for article (PubMed ID: 20858113)
1. Development of biodegradable controlled release scleral systems of triamcinolone acetonide.
Blatsios G; Tzimas AS; Mattheolabakis G; Panagi Z; Avgoustakis K; Gartaganis SP
Curr Eye Res; 2010 Oct; 35(10):916-24. PubMed ID: 20858113
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable scleral implants as new triamcinolone acetonide delivery systems.
Felt-Baeyens O; Eperon S; Mora P; Limal D; Sagodira S; Breton P; Simonazzi B; Bossy-Nobs L; Guex-Crosier Y; Gurny R
Int J Pharm; 2006 Sep; 322(1-2):6-12. PubMed ID: 16824708
[TBL] [Abstract][Full Text] [Related]
3. Improved anti-inflammatory effects in rabbit eye model using biodegradable poly beta-amino ester nanoparticles of triamcinolone acetonide.
Sabzevari A; Adibkia K; Hashemi H; De Geest BG; Mohsenzadeh N; Atyabi F; Ghahremani MH; Khoshayand MR; Dinarvand R
Invest Ophthalmol Vis Sci; 2013 Aug; 54(8):5520-6. PubMed ID: 23833065
[TBL] [Abstract][Full Text] [Related]
4. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
[TBL] [Abstract][Full Text] [Related]
5. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application.
Shen L; You Y; Sun S; Chen Y; Qu J; Cheng L
Ophthalmology; 2010 Dec; 117(12):2365-71. PubMed ID: 20678801
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis.
Shin JP; Park YC; Oh JH; Lee JW; Kim YM; Lim JO; Kim SY
J Ocul Pharmacol Ther; 2009 Jun; 25(3):201-8. PubMed ID: 19456254
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes.
Lee SJ; Kim ES; Geroski DH; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4506-14. PubMed ID: 18503001
[TBL] [Abstract][Full Text] [Related]
8. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
Kamppeter BA; Cej A; Jonas JB
Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
[TBL] [Abstract][Full Text] [Related]
9. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.
Kadam RS; Tyagi P; Edelhauser HF; Kompella UB
Int J Pharm; 2012 Sep; 434(1-2):140-7. PubMed ID: 22633904
[TBL] [Abstract][Full Text] [Related]
10. A novel design of one-side coated biodegradable intrascleral implant for the sustained release of triamcinolone acetonide.
Kim YM; Lim JO; Kim HK; Kim SY; Shin JP
Eur J Pharm Biopharm; 2008 Sep; 70(1):179-86. PubMed ID: 18667297
[TBL] [Abstract][Full Text] [Related]
11. Trans-scleral diffusion of triamcinolone acetonide.
Mora P; Eperon S; Felt-Baeyens O; Gurny R; Sagodira S; Breton P; Guex-Crosier Y
Curr Eye Res; 2005 May; 30(5):355-61. PubMed ID: 16020266
[TBL] [Abstract][Full Text] [Related]
12. Transscleral diffusion of triamcinolone.
Falavarjani KG; Modarres M
Ophthalmology; 2011 Jul; 118(7):1487; author reply 1487-1487.e1. PubMed ID: 21724056
[No Abstract] [Full Text] [Related]
13. Preparation, characterization, and in vivo evaluation of triamcinolone acetonide microspheres after intravitreal administration.
Zarei-Ghanavati S; Malaekeh-Nikouei B; Pourmazar R; Seyedi S
J Ocul Pharmacol Ther; 2012 Oct; 28(5):502-6. PubMed ID: 22537291
[TBL] [Abstract][Full Text] [Related]
14. Intraocular availability of triamcinolone acetonide after intravitreal injection.
Jonas JB
Am J Ophthalmol; 2004 Mar; 137(3):560-2. PubMed ID: 15013884
[TBL] [Abstract][Full Text] [Related]
15. Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection.
Silva PS; Singh RJ; Bakri SJ; Lising RS; Santiago DE; Uy HS
Ocul Immunol Inflamm; 2009; 17(3):216-20. PubMed ID: 19585367
[TBL] [Abstract][Full Text] [Related]
16. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection.
Cheng L; Banker AS; Martin M; Kozak I; Freeman WR
Ophthalmology; 2009 Jul; 116(7):1356-9. PubMed ID: 19450879
[TBL] [Abstract][Full Text] [Related]
17. Persistent depot of triamcinolone acetonide after a single intravitreal injection.
Vedantham V; Kolluru C; Ramasamy K
Indian J Ophthalmol; 2005 Mar; 53(1):65-6. PubMed ID: 15829753
[TBL] [Abstract][Full Text] [Related]
18. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection.
Beer PM; Bakri SJ; Singh RJ; Liu W; Peters GB; Miller M
Ophthalmology; 2003 Apr; 110(4):681-6. PubMed ID: 12689886
[TBL] [Abstract][Full Text] [Related]
19. Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix.
Meng Y; Sun S; Li J; Nan K; Lan B; Jin Y; Chen H; Cheng L
Acta Biomater; 2014 Jan; 10(1):126-33. PubMed ID: 24076072
[TBL] [Abstract][Full Text] [Related]
20. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies.
Araújo J; Garcia ML; Mallandrich M; Souto EB; Calpena AC
Nanomedicine; 2012 Aug; 8(6):1034-41. PubMed ID: 22115598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
